<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by The Biotech Forum on Medium]]></title>
        <description><![CDATA[Stories by The Biotech Forum on Medium]]></description>
        <link>https://medium.com/@biotech_forum?source=rss-38929c3b8ce2------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*9P2rQgdLybfAF-vw9eVi3w.png</url>
            <title>Stories by The Biotech Forum on Medium</title>
            <link>https://medium.com/@biotech_forum?source=rss-38929c3b8ce2------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sun, 22 Nov 2026 21:50:04 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@biotech_forum/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[3 Investment Themes Emerging Early In 2017]]></title>
            <link>https://medium.com/@biotech_forum/3-investment-themes-emerging-early-in-2017-5a7e49ad341a?source=rss-38929c3b8ce2------2</link>
            <guid isPermaLink="false">https://medium.com/p/5a7e49ad341a</guid>
            <category><![CDATA[stocks]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[finance]]></category>
            <category><![CDATA[stock-market]]></category>
            <dc:creator><![CDATA[The Biotech Forum]]></dc:creator>
            <pubDate>Mon, 09 Jan 2017 23:10:22 GMT</pubDate>
            <atom:updated>2017-01-09T23:10:22.611Z</atom:updated>
            <content:encoded><![CDATA[<p>Jan. 9, 2017 11:54 AM ET</p><p><em>“Give a man a beer, waste an hour. Teach a man to brew, and waste a lifetime!</em>” — Bill Owen</p><p>2016 was a tumultuous year which ended with an unexpected election outcome followed by the “Trump Rally” that took all the major indices to all-time highs on the same day late in the year for the first time since 1999. 2017 should be another volatile year given the increasing rise of terrorist attacks in western countries, scheduled elections throughout Europe and still tepid global growth prospects. Domestically, a new administration and congress will have much different priorities and focus areas than have been in place for almost a decade now.</p><p>Although the year is very young, here are three observations about some sectors in the market so far in 2017.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/204/0*jDCnt9BH-HZ8bFpq.jpeg" /></figure><p>1. <strong>The Retail space is full of landmines:</strong></p><p>Retail has gotten off to a punk start to the year even as the overall market has continued to rally. <strong>Macy’s (NYSE: </strong><a href="http://seekingalpha.com/symbol/M"><strong>M</strong></a><strong>)</strong> and <strong>Kohl’s (NYSE: </strong><a href="http://seekingalpha.com/symbol/KSS"><strong>KSS</strong></a><strong>)</strong> both had large sell-offs on last week after reducing guidance on punk holidays sales. The rest of the department store sector and quite a few other retail names staged significant declines in empathy.</p><p>For all the talk in the 2016 election year about NAFTA and unfair trade with China from both parties leading into the November vote, the real job killer in retail seems to be<strong>Amazon (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/AMZN"><strong>AMZN</strong></a><strong>)</strong> not a foreign entity. I think Macy’s will be fine here as their market capitalization looks to be significant under the value of their real estate holdings. Their flagship Herald’s Square store sits on a city block in mid-town Manhattan that has to be worth some $3 billion to $5 billion alone. The stock also yields over four percent which should maintain a floor under the shares. This news will boost efforts to sell off non-performing stores and monetize the real estate they sit on. This will also mean, unfortunately, significant layoffs. At around $30.00 a share, Macy’s seems a good deep value play and one that will pay a larger dividend than most utility stocks these days.</p><p><strong>Children’s Place (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/PLCE"><strong>PLCE</strong></a><strong>)</strong> and <strong>Gap (NYSE:</strong><a href="http://seekingalpha.com/symbol/GPS"><strong>GPS</strong></a><strong>)</strong> seem to be some of the few winners this holiday season among the bricks &amp; mortar retail set. It is a sector I continue to be very underweight weight in within my own portfolio. One of the few retail plays I actually own here is brand management group <strong>Sequential Brands Group (NASDAQ: </strong><a href="http://seekingalpha.com/symbol/SQBG"><strong>SQBG</strong></a><strong>).</strong> The company digested numerous acquisitions made in 2015 last year. This year that integration should pay off. Earnings should go from under 40 cents a share this year to over 50 cents a share in FY2017. The stock sells for less than $5.00 a share. The stock also saw some $500,000 in insider buying in November.</p><p>2. <strong>Rising interest rates might not be a blip this time around:</strong></p><p>The yield on the ten-year treasury has gone from just over 1.3% near the end of the first half of 2016 to 2.4%. Rates have boosted by better GDP numbers in the second half of the year as well as the prospects of better economic growth under the new administration provided it can deliver tax &amp; regulatory reform.</p><p>Unlike the myriad head fakes in past years, I think higher rates and better economic growth will pan out in 2017. This will continue to pummel income investors who chased yield in Utility and Consumer Staples stocks and bid those names to stretched valuations. I am totally out of these sectors of the market. REIT investors will also have to be selective as well in a rising interest rate environment.</p><p>On the other hand, banks and other financials are benefiting greatly from rising rates and their positive impacts to net interest rate margins. The prospect of a lighter regulatory touch is also buoying sentiment on the sector. Banks like <strong>J P Morgan (NYSE: </strong><a href="http://seekingalpha.com/symbol/JPM"><strong>JPM</strong></a><strong>)</strong> and <strong>Bank of America (NYSE: </strong><a href="http://seekingalpha.com/symbol/BAC"><strong>BAC</strong></a><strong>)</strong> have rose some 30% since the election. If you don’t own, I would probably wait for a decent pullback to establish positions.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/243/0*9MbwfOO3533Td1qG.jpeg" /></figure><p><strong>Note:</strong> <em>As of the close of the markets Friday, the model-20 stock </em><a href="http://www.insidersforumsa.com/"><em>Insiders Forum</em></a><em>portfolio is now up </em><strong><em>36.62%</em></strong><em>. This almost triples the return of the Russell 2000 (12.58%) since our launch in late June of 2016.</em></p><p><em>This week we are doing deep dives on Tuesday and Thursday on two intriguing biotech stocks with large recent insider buying. To get that analysis, the current Insiders Forum portfolio and a 14 day free trial to the Insiders Forum, please click </em><a href="https://seekingalpha.com/account/research/subscribe?slug=the-insiders-forum"><em>HERE</em></a><em>.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/269/0*WC2sOGWS1uxQh6WC.jpeg" /></figure><p><strong>3. Biotech is off to strong start:</strong></p><p>After a dismal 2016 that saw the main biotech indices drop just over 20% on the year, biotech has had a strong start to 2017 and was up over four percent in the first trading week of the New Year. The combination of a probably uptick in M&amp;A activity across the industry, low historical valuation levels for the large cap concerns in the sector and potential benefits of tax reform have boosted sentiment on biotech to start the year. The end of tax loss selling season has also probably play a part.</p><p>There are myriad bargains to be had across both the large &amp; small cap parts of this arena. Long term core holding <strong>Amgen (NASDAQ: </strong><a href="http://seekingalpha.com/symbol/AMGN"><strong>AMGN</strong></a><strong>)</strong> got some great news late last week. A judge told <strong>Regeneron (NASDAQ: </strong><a href="http://seekingalpha.com/symbol/REGN"><strong>REGN</strong></a><strong>)</strong> that it would have to pull its PCSK9 inhibitor cholesterol drug that competes against Amgen’s Repatha off the market as a penalty in a patent dispute. This permanent injunction is obviously good news for this biotech pioneer &amp; stalwart as Repatha is one of the most important drug launches for the company in years and it had gotten off to a slow start. Obviously, the elimination of the company’s primary competitor in this evolving space should provide a huge boost to its prospects here. I would expect several reissued Buy recommendations on Amgen this week. Biotech remains my highest allocation in my portfolio in 2017.</p><p><em>(click to enlarge)</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*mrSdUR7VSd96D_5V.jpg" /></figure><p><strong>Note:</strong> <em>91 out of the alloted 100 spaces for the special 50% discount offer on the Growth Stock Advisor got filled over the weekend. Investors Alley has graciously extended this offer to get half off the first quarter into the model — 20 stock Growth Stock Advisor portfolio. This portfolio closed out huge gains in names like </em><strong><em>Exelixis (NASDAQ:</em></strong><a href="http://seekingalpha.com/symbol/EXEL"><strong><em>EXEL</em></strong></a><strong><em>)</em></strong><em> and </em><strong><em>Health Insurance Innovations (</em></strong><a href="http://seekingalpha.com/symbol/hiiq"><strong><em>HIIQ</em></strong></a><strong><em>)</em></strong><em> in 2016 among other winners. Just use</em> <em>the coupon code “</em><strong>jensen-half-off-01”</strong> at this <a href="http://www.investorsalley.com/amember/signup/the-growth-stock-advisor-5-biotech-stocks-special"><strong>LINK</strong></a><strong> t</strong>o take advantage of this offer.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/300/0*8SIWDkxWzV6pmSxT.jpeg" /></figure><p>Thank You &amp; Happy Hunting</p><p>Bret Jensen</p><p>Founder, <a href="http://biotechforumsa.com/">Biotech Forum</a> &amp; <a href="http://www.insidersforumsa.com/">Insiders Forum</a></p><p><strong>Disclosure:</strong> I am/we are long AMGN, M, SQBG.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5a7e49ad341a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[3 Comeback Stories For 2017]]></title>
            <link>https://medium.com/@biotech_forum/3-comeback-stories-for-2017-2218d7b23858?source=rss-38929c3b8ce2------2</link>
            <guid isPermaLink="false">https://medium.com/p/2218d7b23858</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[stock-market]]></category>
            <category><![CDATA[stocks]]></category>
            <dc:creator><![CDATA[The Biotech Forum]]></dc:creator>
            <pubDate>Mon, 02 Jan 2017 22:58:18 GMT</pubDate>
            <atom:updated>2017-01-02T22:58:18.498Z</atom:updated>
            <content:encoded><![CDATA[<p>Jan. 2, 2017 10:13 AM ET|Includes:<a href="http://seekingalpha.com/symbol/AGN">Allergan plc (AGN)</a>, <a href="http://seekingalpha.com/symbol/MYL">MYL</a>, <a href="http://seekingalpha.com/symbol/SIG">SIG</a>, <a href="http://seekingalpha.com/symbol/TEVA">TEVA</a></p><p><em>“You hear about how many fourth quarter comebacks that a guy has and I think it means a guy screwed up in the first three quarters</em>.”- Peyton Manning</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/115/0*3JMiSU78j2DPsL9X.jpeg" /></figure><p>The NFL regular season has drawn to a close. In no sport do fans see such change of fortunes on a year-to-year basis. Injuries, scheduling, penalties and just plain bad bounces play more of role in determining your team’s fortune than any sport I know of.</p><p>Take the 2016 season for example. Three of the four teams that made their conference championships last year, didn’t even make the playoffs this year and two did not even finish over .500. Last year’s Superbowl winner, the Denver Broncos, not only failed to make the playoffs but came in third in their own division. Meanwhile the Dallas Cowboys who were at the bottom of their division last year have the NFC’s #1 seed in the playoffs.</p><p>The stock market can functionally similarly in that this year’s big loser can become next year’s big winner. This is one reason the so called “Dogs of the Dow” are so popular as they have consistently outperformed the Dow Jones Industrial Average over the decades. In that vein, I have perused the worst 25 performers in the S&amp;P 500 in 2016 to find next year’s version of this year’s Dallas Cowboys.</p><p>Not surprisingly given the dismal performance of biotech &amp; pharma plays over the past 12 to 18 months, this list is dominated by these sectors in 2016. Which names can make a comeback in 2017? Here are a few ideas for the New Year.</p><p>Let’s start with <strong>Allergan (NYSE: </strong><a href="http://seekingalpha.com/symbol/AGN"><strong>AGN</strong></a><strong>)</strong> which has already started to move up in recent weeks as tax loss selling has started to ebb but the stock is still down a third from where it started the year. The Irish drug giant had a tough start of the year as it became the “poster boy” for so called tax inversions in an election year. In April, after three tries, the Treasury Department then derailed its mega-merger with <strong>Pfizer (NYSE: </strong><a href="http://seekingalpha.com/symbol/PFE"><strong>PFE</strong></a><strong>).</strong></p><p>However, 2016 was not a lost year. The company did complete its sale of its generic drug business to <strong>Teva Pharmaceuticals (NASDAQ: </strong><a href="http://seekingalpha.com/symbol/TEVA"><strong>TEVA</strong></a><strong>)</strong> for some $40 billion. Lately, it has put those proceeds to work in bolstering its pipeline and growth prospects through a series of small acquisitions including privately held LifeCell for $2.9 billion earlier in December. I expect the company to continue to be active in the M&amp;A space in 2017.</p><p>The company also plans to initiate a dividend in the first half of 2017, providing a yield of approximately 1.5% which could attract some income investors into this value stock. Allergan should deliver earnings from continuing operations of just under $14.00 a share in FY2016. Earnings should rise in the low teens in FY2017 as the drug giant sees faster growth now that it no longer has the generic drug side to its business. Despite its growth prospects, the shares trade at a significant discount to the overall market multiple. I think that discount gets eliminated in the New Year.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/167/0*kXckPqZXWfTGyBs1.jpeg" /></figure><p><strong>Note:</strong> Y<em>esterday we </em><a href="http://seekingalpha.com/instablog/498952-bret-jensen/4946105-3-key-reasons-biotech-will-bounce-back-2017"><em>noted</em></a><em> that the Biotech Forum was 9 individuals short of achieving 500 members in our small, but fast growing community and that we were enabling two week free trials until we achieved that goal. Well, we came up a FG short — the story of my beloved Arizona Cardinals this year.</em></p><p><em>This means there are still </em><strong><em>3</em></strong><em> slots available on a first come, first served basis left. The model 20-stock Biotech Forum portfolio has outperformed the largest biotech ETF by over 1,000 basis points since its launch in April of 2015. The Live Chat community is populated by scores of biotech investors swapping investment ideas throughout the trading day as well. Forum membership also entitles you to exclusive deep dive analysis on attractive small cap opportunities as well as many “first look” features.</em></p><p><em>If one of your New Year’s “resolutions” was to become a better biotech investor in 2017, please click </em><a href="http://seekingalpha.com/author/bret-jensen/research"><strong><em>HERE</em></strong></a><em> for your free test run of the Biotech Forum.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/146/0*_4sViCmL_nV2Vkci.jpeg" /><figcaption>www.biotechforumsa.com</figcaption></figure><p><strong>Mylan (NYSE: </strong><a href="http://seekingalpha.com/symbol/MYL"><strong>MYL</strong></a><strong>)</strong> suffered a comparable decline to Allergan in 2016. Similarity, it was punished by political rhetoric and had to provide sub-committee testimony about the pricing on its EpiPen product. The company did move to lessen these concerns by expanding its patient access programs and coming out with a generic version of the EpiPen at half the branded cost.</p><p>I think investors will move on from these worries in 2017. The company’s purchase of Meda in 2016 gives it an expanded footprint in Europe and important emerging markets like Russia. In addition, EpiPen sales will account for less than 10% of overall revenue in the New Year. The stock is cheap no wonder how you want to slice it. The shares sell at eight times earnings. Profit growth was flat this year but should rebound to 10% to 15% next year on a similar surge in revenues. This generic drug giant does not deserve to sell at less than half of the overall market multiple given this and the stock should reward patient shareholders in 2017.</p><p>Outside the pharma space, <strong>Signet Jewelers (NYSE: SIG</strong>) had a rough year as a so-called “diamond swapping” scandal tainted the shares which dropped more than 20% on the year. However, these actions only appear to have happened at a limited number of stores. They also have had a lower impact on sales as originally feared.</p><p>The shares have moved up over 20% from their lows this summer where several insiders added to their core stakes. Signet is by far the market share leader in a very fragmented industry giving it economies of scale and room to grow via strategic small acquisitions. It currently holds 17% of the market. That is triple the share of the next closest competitor, <strong>Tiffany (NYSE: </strong><a href="http://seekingalpha.com/symbol/TIF"><strong>TIF</strong></a><strong>).</strong> Earnings were flat this year, but should see at least a 10% bounce in 2017. The stock trades at less than 12 times forward earnings with just over a one percent dividend yield. Over the past five years, the shares have averaged a 15 forward earnings multiple.</p><p>And those are three names that should get off the schneid in 2017 and outperform the market after rather dismal years in 2016.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/300/0*HGDUIJsXLnWa6XVp.jpeg" /></figure><p>Thank You &amp; Happy Hunting<br>Bret Jensen</p><p>Founder, <a href="http://biotechforumsa.com/">Biotech Forum</a> &amp; <a href="http://www.insidersforumsa.com/">Insiders Forum</a></p><p><strong>Disclosure:</strong> I am/we are long AGN, MYL, SIG, TEVA.</p><p>Stocks: <a href="http://seekingalpha.com/symbol/AGN">AGN</a>, <a href="http://seekingalpha.com/symbol/MYL">MYL</a>, <a href="http://seekingalpha.com/symbol/SIG">SIG</a>, <a href="http://seekingalpha.com/symbol/TEVA">TEVA</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2218d7b23858" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Christmas Comes Early For These 3 Small Biotech Stocks]]></title>
            <link>https://medium.com/@biotech_forum/christmas-comes-early-for-these-3-small-biotech-stocks-be81ac8acea1?source=rss-38929c3b8ce2------2</link>
            <guid isPermaLink="false">https://medium.com/p/be81ac8acea1</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[stocks]]></category>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[finance]]></category>
            <category><![CDATA[stock-market]]></category>
            <dc:creator><![CDATA[The Biotech Forum]]></dc:creator>
            <pubDate>Sat, 24 Dec 2016 16:26:42 GMT</pubDate>
            <atom:updated>2016-12-24T16:26:42.219Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/71/0*64fns3vQSVzA4-eZ.jpeg" /></figure><p><em>“I like coffee because it gives me the illusion that I might be awake</em>.” — <a href="https://en.wikipedia.org/wiki/Lewis_Black">Lewis Black</a></p><p>Christmas came early this week for the shareholders of these small biotech stocks on Friday.</p><p>First, <strong>Portola Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/PTLA"><strong>PTLA</strong></a><strong>)</strong> went up by some 33% on Friday. The trigger was the news that the FDA had accepted betrixaban for priority review for the treatment of extended-duration prophylaxis of venous thromboembolism {VTE} in acute medically ill patients with risk factors for VTE. A priority review shortens the review period to six months from the standard ten months. Betrixaban’s PDUFA date for this indication is now June 24th, 2017.</p><p>Additionally, Portola announced that the European Medicines Agency has validated its Marketing Authorization Application for betrixaban for extended-duration prophylaxis of VTE in adults with acute medical illness and risk factors for VTE. This twin dosed of good news caused the stock to spike some 33% Friday, a very nice early Christmas present for Portola’s shareholders and a good omen for the New Year.</p><p>They said timing is everything in life, and we certainly had that on our view on Portola. We had done an optimistic piece on Portola heading into 2017 on <a href="http://seekingalpha.com/instablog/498952-bret-jensen/4943293-important-catalyst-portola-pharmaceuticals">Tuesday</a>. With confidence that the recent Complete Response Letter around the manufacturing issues around Andexxa will be soon resolved and this unexpected good news around Betrixaban; 2017 is setting up as a very good year for Portola’s shareholders.</p><p><strong>Note:</strong> <em>Portola was one of eight small cap positions in the Biotech Forum’s 15 small cap holdings that surged at least seven percent on Friday (two more were up “only” 5%). In the spirit of the holidays, we are giving out free two week trials into this top-ranked offering through midnight Monday. If interested in becoming a better biotech investor, please activate your risk-free 14 day trial offer</em> <a href="http://seekingalpha.com/author/bret-jensen/research"><strong>HERE</strong></a>.</p><p><strong>Synergy Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/SGYP"><strong>SGYP</strong></a><strong>)</strong>, another member of the Biotech Forum portfolio, was up more than 20% on Friday. After the bell on Thursday, the company announced positive results in its second Phase III trial using plecanatide to treat iirritable bowel syndrome with constipation (IBS-C). The results echoed the positive results from the first Phase 3 trial that came out approximately two weeks ago.</p><p>Plecanatide is currently under review to treat chronic ideopathic constipation. It has a PDUFA date of January 29th, at which time I expect plecanatide to be approved for that indication. In trials the compound has shown it is as or more effective than the current standard “Linzess” and has less side effects such as diarrhea. If approved, the company will filed a supplementary NDA for IBS-C sometime in the first quarter and I also expect that to be approved by the FDA. Linzess did $150 million in <a href="http://seekingalpha.com/pr/16569965-ironwood-pharmaceuticals-provides-second-quarter-2016-investor-update">net sales</a> in the United States in the second quarter.</p><p>One reason the stock surged on Friday, as this news make Synergy a more likely buyout target. The company has been a consistent target of buyout rumors in 2016. One rumored interested suitor has been <strong>Allergan (NYSE:</strong><a href="http://seekingalpha.com/symbol/AGN"><strong>AGN</strong></a><strong>)</strong> who has been very active in the M&amp;A arena recently and has stated its desire to expand into the gastrointestinal space. In my opinion, a more likely suitor is Takeda who has articulated it has ~$15 billion to spend on acquisitions and was recently involved in negotiations to buy Valeant’s GI business for some $10 billion. Synergy may not make it through 2017 as a standalone entity, which I am sure its shareholders will be okay with.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/136/0*ZKYnsDAI0qxscD9P.jpeg" /></figure><p><strong>Note:</strong> <em>There are now only 7 days left to try out the Insiders Forum on a 14 day free trial offer and lock in perpetually our low rates before they go up $50/annually or $5/month starting January 1st. As of the market close yesterday, the portfolio is now up </em><strong><em>36.22%</em></strong><em> since its launch late in June. This almost triple the return of Russell 2000 over that time span.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*w9rt_a2VRC6Io4TqiB7JGA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/190/0*vCmR7rtGcprrYoOR.png" /><figcaption>www.insidersforumsa.com</figcaption></figure><p><em>We closed out our fifth winning position in the Insiders Forum portfolio Friday. We will be adding two new holdings to the portfolio over the next ten days. To sign up for your risk-free two week trial, please click</em> <a href="https://seekingalpha.com/account/research/subscribe?slug=the-insiders-forum">HERE</a>.</p><p>Finally, <strong>Progenics Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/PGNX"><strong>PGNX</strong></a><strong>)</strong> which I recently <a href="http://seekingalpha.com/instablog/498952-bret-jensen/4934605-progenics-pharmaceuticals-next-stop-10">profiled</a> on these pages, came through with its own encouraging results from its developmental pipeline late Thursday. The stock rallied eight percent on Friday after an independent monitoring committee completed its <a href="http://seekingalpha.com/news/3232315-progenics-plus-11-percent-hours-trial-green-lighted-continue">review</a> of an interim analysis of the ongoing Phase 3 trial of Progenics’ prostate cancer imaging agent “1404” and recommended the trial continue.</p><p>To recap the investment case for Progenics. Oral relistor was approved by the FDA on July 19th. This is already triggering a substantial boost in sales at marketing and distributing partner <strong>Valeant Pharmaceuticals (NYSE:</strong><a href="http://seekingalpha.com/symbol/VRX"><strong>VRX</strong></a><strong>)</strong> which also just announced it is increasing its sales force in the treatment area. This should boost relistor sales further. This will cause royalties to rise nicely in the quarters ahead and accelerate the timeline Progenics can earn some $200 million in additional sales milestones.</p><p>Second, Azedra which is a late stage compound for the treatment of a couple of rare cancers, should release trial results in the first quarter. They are highly likely to be positive and this new compound could hit the market before 2017 is complete.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*g6hsKHmO1zPJRjc_.jpg" /></figure><p>1404 has the potential to be targeted at a larger market than either relistor or Azedra. As noted in my previous article, the market is giving Progenics no value for this potential. Therefore, even though PGNX is up some 80% in recent months; it still is one of my favorite small cap biotech stocks heading into 2017.</p><p>Thank You &amp; Happy Hunting</p><p>Bret Jensen<br>Founder, <a href="http://biotechforumsa.com/">Biotech Forum</a> &amp; <a href="http://www.insidersforumsa.com/">Insiders Forum</a></p><p><strong>Disclosure:</strong> I am/we are long PGNX, PTLA, SGYP.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=be81ac8acea1" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Omeros Corporation: Why This $11 Biotech Has Substantial Upside — Bret Jensen]]></title>
            <link>https://medium.com/@biotech_forum/omeros-corporation-why-this-11-biotech-has-substantial-upside-bret-jensen-a8d6f3707cc8?source=rss-38929c3b8ce2------2</link>
            <guid isPermaLink="false">https://medium.com/p/a8d6f3707cc8</guid>
            <category><![CDATA[investment]]></category>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[stocks]]></category>
            <category><![CDATA[stock-market]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[The Biotech Forum]]></dc:creator>
            <pubDate>Sat, 25 Jun 2016 13:51:32 GMT</pubDate>
            <atom:updated>2016-06-25T13:51:32.644Z</atom:updated>
            <content:encoded><![CDATA[<p>It is nice to see a large rally today on confidence that the polls are correct and the U.K. does indeed vote to stay in the European Union. Although I can certainly understand the Brits desire to leave what has become an often ineffective and increasingly bureaucratic entity headquartered in Brussels, the last thing the global currency and equity markets needed right now is this sort of event that could have triggered significant volatility. We will hope investors have made the right bet and get confirmation of the victory of the “remain” faction when polls close at 5pm eastern standard time in the U.K. If not, it could be a very brutal day of trading Friday.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/600/1*zSWrrtaj5gC-Yn-hIGe9rg.png" /><figcaption><strong>REGISTER FOR THIS FREE REPORT:</strong> <a href="http://bit.ly/OMERReport">http://bit.ly/OMERReport</a></figcaption></figure><p>One sector that has reacted very positively to this development is biotech which is up more than one and a half percent today as we head to the close. If polls are correct, this rally should continue into Friday given how beaten down the sector has become. We just issued a newly released 12 page report on why we think a small biotech concern called <strong>Omeros Corporation (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/OMER"><strong>OMER</strong></a><strong>)</strong> which is currently trading at just ~$11 share has substantial upside ahead of it. I offer it up free <a href="http://bit.ly/OMERReport">here</a> as food for thought and for consideration going into end of the week trading as we await confirmation from England that the rally can continue when trading resumes on Friday.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/131/1*unbu4U97fnwU1HFN6zziIQ.png" /><figcaption>Bret Jensen</figcaption></figure><p>Thank You &amp; Happy Hunting<br>Bret Jensen<br>Founder, <a href="https://seekingalpha.com/account/research/subscribe?slug=bret-jensen&amp;source=bret_jensen_vurl">Biotech Forum</a></p><p><a href="https://seekingalpha.com/account/research/subscribe?slug=bret-jensen&amp;source=bret_jensen_vurl"><strong>For more information on Bret’s core investing strategy that is hugely successful in the lucrative biotech sector, consider Bret Jensen’s exclusive investment service, The Biotech Forum on Seeking Alpha.</strong></a></p><p><strong>Disclosure:</strong> I am/we are long OMER.<br>Stocks: <a href="http://seekingalpha.com/symbol/OMER">OMER</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a8d6f3707cc8" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Possible Takeout Targets in Biotech Land — Bret Jensen]]></title>
            <link>https://medium.com/@biotech_forum/possible-takeout-targets-in-biotech-land-bret-jensen-677cb234a350?source=rss-38929c3b8ce2------2</link>
            <guid isPermaLink="false">https://medium.com/p/677cb234a350</guid>
            <category><![CDATA[stock-market]]></category>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[finance]]></category>
            <dc:creator><![CDATA[The Biotech Forum]]></dc:creator>
            <pubDate>Tue, 14 Jun 2016 19:21:01 GMT</pubDate>
            <atom:updated>2016-06-14T19:21:01.056Z</atom:updated>
            <content:encoded><![CDATA[<p>Jun 14, 2016 8:20 AM | about stocks: <a href="http://seekingalpha.com/symbol/IBB">IBB</a></p><p><strong>Note:</strong> A free 10 page report has just been published on an attractive ~$5 biopharma stock with an important PDUFA date coming up in July which could power significant capital appreciation. It is mentioned briefly below but we go into granular analysis in the report. To download that free report just click <a href="http://bit.ly/PGNXReport">here</a>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/849/1*p505fqP0M6mTnA2olM7PiQ.jpeg" /><figcaption>www.bretjenseninvests.com</figcaption></figure><ul><li>We are starting to see some of the “animal spirits” coming back into the biotech sector after this sector’s deepest and longest bear market since the financial crisis. The Treasury Department and the election season have made mega-mergers impossible to get through regulatory agencies, so the biotech and pharma giants are starting to concentrate in the small and mid-cap space by making what some call “bolt on” acquisitions</li><li><strong>AbbVie (NYSE:</strong><a href="http://seekingalpha.com/symbol/ABBV"><strong>ABBV</strong></a><strong>)</strong> helped start this new wave when it purchased privately held StemCentrix for almost $6 billion in late April to expand their pipeline into oncology. In May <strong>Pfizer (NYSE:</strong><a href="http://seekingalpha.com/symbol/PFE"><strong>PFE</strong></a><strong>)</strong> paid over $5 billion to acquire <strong>Anacor Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/ANAC"><strong>ANAC</strong></a><strong>).</strong> Pfizer paid a 60% premium for the pleasure. The company has one product on the market. The driver of the acquisition is a compound called Eucrysa, an eczema cream currently before US regulators for approval as well as psoriasis agent AN2898 in Phase II development. Pfizer believes Eucrysa could eventually do $2 billion in peak annual sales.</li><li>Outside the mid-caps in the industry, the smaller concerns are also getting some play. <strong>Xenoport (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/XNPT"><strong>XNPT</strong></a><strong>),</strong> which has an approved product for restless leg syndrome, and has compounds in the pipeline targeting psoriasis, multiple sclerosis and Parkinson’s disease. Privately held Arbor Pharma paid an approximate 60% premium to purchase Xenoport.</li><li>On the last day of May, <strong>Jazz Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/JAZZ"><strong>JAZZ</strong></a><strong>)</strong> has agreed to pay $30.25 a share to acquire <strong>Cellator Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/CPXX"><strong>CPXX</strong></a><strong>)</strong> whose stock closed Friday at $17.50 a share. Up until March of this year, the shares spent a good portion of their previous two years available at under $2.50 a share. This company’s main asset is VYXEOS. This is the first product candidate to demonstrate a statistically significant improvement in overall survival in patients with high-risk (secondary) AML and has Orphan Drug Status in both the United States and Europe.</li><li>The uptick in purchase activity focused on the small and mid-cap concerns in the space makes logical sense. Large biotech and pharma players need to replenish their pipelines, they are flush with cash and bargains abound after the deep bear market in this area of the market. In short, the M&amp;A genie seems to back out of the bottle in this beaten down sector of the market which should bode very well for future capital appreciation in the small and mid-cap part of the market as M&amp;A helps sentiment move into “risk on” mode once again.</li><li>So who in the small and mid-cap space is a logical acquisition target? Oncology concern <strong>Medivation (MDVN</strong>) has to be on the short “list” given it has already rejected <strong>Sanofi’s (NYSE:</strong><a href="http://seekingalpha.com/symbol/SNY"><strong>SNY</strong></a><strong>)</strong> $9.3 billion takeover offer and that company has now gone “hostile” and is trying to replace Medivation’s board with one that is more open to negotiations. In addition, several drug giants have been mentioned as possible “white knights” in anticipation of a possible bidding war. The stock has roughly doubled over the past three months, so upside seems limited here.</li><li><strong>Ionis (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/IONS"><strong>IONS</strong></a><strong>)</strong> is another mid-cap that has been speculated often in 2016 as a possible target. However, in late May safety concerns that emanated from a key late stage trial puts a good portion of the company’s underlying technology and pipeline candidates in question. Until these questions get resolved, it is hard to see a larger player making a bid for this concern.</li><li><strong>Acadia Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/ACAD"><strong>ACAD</strong></a><strong>)</strong> is yet another mid-cap concern that has come under intense speculation as a buyout candidate and a who’s who of the biotech and pharma world are rumored to be very interested in a possible acquisition of this mid-cap concern with just over a $4 billion market capitalization. Its first commercialized product “Nuplazid” just hit the market. It is the first approved treatment for the psychosis associated with Parkinson’s, a potential billion-dollar indication. The compound is also in Phase II development for treating the same condition in the Alzheimer’s and Schizophrenia populations. <strong>AstraZeneca (NYSE), Biogen (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/BIIB"><strong>BIIB</strong></a><strong>)</strong> and <strong>Teva Pharmaceuticals (NYSE:</strong><a href="http://seekingalpha.com/symbol/TEVA"><strong>TEVA</strong></a><strong>)</strong> have all been speculated as likely suitors.</li><li>In the small cap space, one has to watch what <strong>Allergan (NYSE:</strong><a href="http://seekingalpha.com/symbol/AGN"><strong>AGN</strong></a><strong>)</strong> is doing right now. It has already been fairly active in smaller deals since its merger with Pfizer was called in April off thanks to new rules around “tax inversions”. It has also publicly stated it is focusing on “tuck in” acquisitions to expand its presence in four key focus areas.</li><li>One of these is the gastrointestinal space. <strong>Synergy Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/SGYP"><strong>SGYP</strong></a><strong>)</strong>makes a logical target for this drug giant. Its primary compound “plecanatide” should be approved Chronic idiopathic constipation in January. The same drug candidate should have a Phase III trial readout for Irritable Bowel Syndrome with constipation later this month. With a market cap of $600 million, Synergy certainly meets the criteria of a “tuck in” acquisition.</li><li>I also like <strong>Progenics Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/PGNX"><strong>PGNX</strong></a><strong>)</strong> as an undervalued play in this space with a $325 million market capitalization. Its distribution deal for its primary compound relistor with pariah <strong>Valeant Pharmaceuticals (NYSE:</strong><a href="http://seekingalpha.com/symbol/VRX"><strong>VRX</strong></a><strong>)</strong> makes a buyout a bit more complicated. However, Valeant is said to be looking for assets to sell to pay down its large $30 billion debt load. Relistor is currently available only in an injectable form but is doing more than $15 million a quarter in sales and growing nicely. The oral version of relistor should be approved by the FDA next month which should exponentially boost sales.</li><li>This approval also will trigger a $50 million milestone payout to Progenics from Valeant. The company also stands to make $200 million in additional sales milestones and already has some $75 million in cash on hand and an interesting pipeline beyond relistor. Add in a 15% to 19% royalty stream on all relistor sales and you have an undervalued stock and a possible logical acquisition target even though it might have to be a two-step process.</li></ul><p>Thank You &amp; Happy Hunting</p><p>Bret Jensen<br>Founder, <a href="https://seekingalpha.com/account/research/subscribe?slug=bret-jensen&amp;source=bret_jensen_vurl">Biotech Forum</a></p><p>Stocks: <a href="http://seekingalpha.com/symbol/IBB">IBB</a></p><p><a href="https://seekingalpha.com/account/research/subscribe?slug=bret-jensen&amp;source=bret_jensen_vurl"><strong>For more information on Bret’s core investing strategy that is hugely successful in the lucrative biotech sector, consider Bret Jensen’s exclusive investment service, The Biotech Forum on Seeking Alpha.</strong></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=677cb234a350" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Investment Case On Relypsa Gets Much Stronger. A Buyout Ahead? — Bret Jensen]]></title>
            <link>https://medium.com/@biotech_forum/the-investment-case-on-relypsa-gets-much-stronger-a-buyout-ahead-bret-jensen-ebd11eed19fb?source=rss-38929c3b8ce2------2</link>
            <guid isPermaLink="false">https://medium.com/p/ebd11eed19fb</guid>
            <category><![CDATA[finance]]></category>
            <category><![CDATA[stock-market]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[The Biotech Forum]]></dc:creator>
            <pubDate>Wed, 01 Jun 2016 02:25:24 GMT</pubDate>
            <atom:updated>2016-06-01T02:32:29.971Z</atom:updated>
            <content:encoded><![CDATA[<p>Originally Published: May 29, 2016</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/574/0*5TkvN-L6DQMbg8mj.jpg" /></figure><p>This week one of my favorite biopharma companies was the recipient of not one but two positive events that enhances both the near and medium term prospects for Relypsa. The company <a href="http://seekingalpha.com/news/3185655-relypsa-submits-snda-fda-seeking-veltassa-labeling-change-reducing-dose-separation-three">filed</a> a supplemental New Drug Application (sNDA) to reduce the block label on its primary and only drug Veltassa to lower the need for drug interaction with other oral medications from 6 hours to 3 hours after study results supported that claim. In most cases, there was no drug interaction at all I expect the FDA to grant that request which will make Veltassa slightly more attractive to prescribing physicians.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/467/0*RaYI26NDI7YTrLtw.jpg" /></figure><p>The bigger news is <strong>AstraZeneca (NYSE:</strong><a href="http://seekingalpha.com/symbol/AZN"><strong>AZN</strong></a><strong>)</strong> <a href="http://seekingalpha.com/news/3186023-fda-rejects-astrazenecas-zsminus-9-nda-competitor-relypsa-29-percent-premarket">received</a> a complete response letter (‘CRL’) around ZS-9. Based on the conversation I had with an expert who is an investment banker in the space, this could keep this competitor off the market until the first or second quarter of 2017. This will give Veltassa more than a year to establish itself in the hyperkalemia market without facing competition.</p><p>That said, I expect the stock to be volatile in the months ahead as it ebbs and flows around the latest buyout rumor or monthly script count. I project that the stock will trade in a fairly wide range of $15 to $25 a share in the coming months. My long term thesis still is Relypsa will eventually be bought out at a much higher price.</p><p>Obviously Relypsa is in a much better negotiating position with any potential suitors due to these two events. Although I expect buyout rumors to escalate thanks to the CRL on ZS-9, I don’t believe an acquisition to occur over the next month or two. The most rumored acquisition partner out of several so far in 2016 has been French drug maker<strong>Sanofi (NYSE:</strong><a href="http://seekingalpha.com/symbol/SFY"><strong>SFY</strong></a><strong>).</strong> That company is locked into a takeover attempt of oncology concern<strong>Medivation (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/MDVN"><strong>MDVN</strong></a><strong>).</strong> After Medivation rejected its $9.3 billion offer and refused to enter into negotiations, Sanofi is attempting to replace that company’s board with a friendlier slate of directors.</p><p>The pursuit of Medivation will likely consume any of Sanofi’s M&amp;A efforts for the time being and this drama could stretch out over the next few months. However, if any of the rumored “white knights” like <strong>Amgen (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/AMGN"><strong>AMGN</strong></a><strong>)</strong> or <strong>Celgene (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/CELG"><strong>CELG</strong></a><strong>)</strong>come to the rescue and bump out Sanofi, I would look for the firm to quickly circle back to smaller acquisitions such as Relypsa to put the pain and embarrassment of losing out on Medivation quickly behind it. There also have been other rumored potential suitors over the past six months for Relypsa.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*3Pw3NL4EU2wRfYi3.jpg" /></figure><p>In the meantime, Relypsa will continue to expand Veltassa sales which should get a boost as more specialists test out the drug on a few patients with hyperkalemia in their care before rolling it out to their wider practice. It also usually takes at least six months before a new drug gets into the reimbursement network of all the major payers, this is especially true of Medicare Part D providers. As we get through summer, coverage will continue to improve which should also boost sales.</p><p>The unexpected CRL for ZS-9 also got the notice of the analyst community on Friday, May 27th. Cowen &amp; Co., Cantor Fitzgerald and BTIG all reiterated their Buy ratings on Friday with price targets ranging from $35 to $41 on Relypsa. Permabear Andrew Behrens at Morgan Stanley even hedged his bets a few days earlier in the week by removing his longstanding “Sell” rating for a more benign Neutral rating.</p><p>In reiterating her Buy rating and $41 price target (more than 100% upside), the analyst at Cantor <a href="http://www.smarteranalyst.com/2016/05/27/analysts-weigh-in-on-two-rising-pharma-stocks-titan-pharmaceuticals-inc-ttnp-relypsa-inc-rlyp/">noted</a> “The approval delay of potential Veltassa competitor ZS-9 is an unexpected development, and likely to be a positive factor for share price appreciation, in our view. While we think a second “voice” would be likely to grow the market overall, the lack of competition will go a long way in removing what we see as an overhang on RLYP’s valuation and possibly drive short covering. We think Relypsa’s shares reflect execution risk for Veltassa’s launch in spite of what we see as a positive trend line. We continue to believe that Veltassa sales will be back-end loaded in 2016, and the ultimate arrival of ZS-9 in the market at some point is likely to serve as a positive driver of market growth overall.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*YNkivpgZSh95EJPH.jpg" /></figure><p>We at the Biotech Forum agree with this assessment. Regardless of when ZS-9 is approved, we believe that Veltassa will be the dominant player in the larger Chronic part of the hyperkalemia market. Given these late breaking events, we wanted to provide an updated addendum to our original <a href="http://bit.ly/RELYPSA">in depth report</a> on Relypsa as the strong investment thesis on this undervalued biopharma stock got demonstrably stronger last week.</p><blockquote><a href="http://bit.ly/RLYPReport">Register your email</a> to receive a 20-page free report on Relypsa’s upside!</blockquote><p><a href="http://seekingalpha.com/instablog/498952-bret-jensen/4886268-investment-case-relypsa-gets-much-stronger-buyout-ahead#17120394"><strong>BONUS</strong></a><strong><br></strong>Below is a report on a small cap developmental company that is typical of the small cap positions we hold within the Biotech Forum portfolio. It was on a ~$4.50 a share oncology concern with multiple upcoming catalysts and a bright future. The stock has since risen to ~$6 a share but is still undervalued and has significant potential upside. This free report can still be found <a href="http://bit.ly/EXELReport">here</a>.</p><p>This is typical of the free 7–10 page investment reports I put out on a weekly basis on small attractive biotech companies. These go into deeper analysis on the some of the more intriguing stocks and trends in this lucrative but volatile area of the market which I have been following and investing successfully in for more than two decades. To get these reports delivered directly to your “in” box when published, just register for free at <a href="http://bretjenseninvests.com/">bretjenseninvests.com</a>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/131/1*unbu4U97fnwU1HFN6zziIQ.png" /><figcaption>Bret Jensen</figcaption></figure><p>Thank You &amp; Happy Hunting</p><p>Bret Jensen<br>Founder, <a href="http://biotechforumsa.com/">Biotech Forum</a></p><p><strong>Disclosure:</strong> I am/we are long RLYP.</p><p>Stocks: <a href="http://seekingalpha.com/symbol/RLYP">RLYP</a></p><p><a href="https://seekingalpha.com/account/research/subscribe?slug=bret-jensen&amp;source=bret_jensen_vurl"><strong>For more information on Bret’s core investing strategy that is hugely successful in the lucrative biotech sector, consider Bret Jensen’s exclusive investment service, The Biotech Forum on Seeking Alpha.</strong></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ebd11eed19fb" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Brutal Sentiment On Biotech Is Unwarranted — Bret Jensen]]></title>
            <link>https://medium.com/@biotech_forum/brutal-sentiment-on-biotech-is-unwarranted-bret-jensen-3dc16db194cb?source=rss-38929c3b8ce2------2</link>
            <guid isPermaLink="false">https://medium.com/p/3dc16db194cb</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[stock-market]]></category>
            <category><![CDATA[investing]]></category>
            <dc:creator><![CDATA[The Biotech Forum]]></dc:creator>
            <pubDate>Fri, 20 May 2016 13:08:14 GMT</pubDate>
            <atom:updated>2016-05-20T13:08:14.466Z</atom:updated>
            <content:encoded><![CDATA[<p>Note: For free weekly 7–10 page reports on small attractive biotech stocks, please just register at <a href="http://www.bretjenseninvests.com/">bretjenseninvests.com</a>. Our last report was on a small oncology concern with the ticker symbol EXEL when it was at ~$4.50 a share. It is now at ~$5.25 and still has upside. Here is that free take <a href="http://bit.ly/EXELReport">http://bit.ly/EXELReport</a></p><p><em>(click to enlarge)</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*gcExdLxqr5dm-DhO.jpg" /></figure><p>I was out at the Money Show in Las Vegas last week during a couple of investment presentations to try to help investors navigate this very challenging market. Judging from the overflowing room for the presentation I did on biotech, interest in this space has not waned a bit and a lot of folks are slowly adding new money to the sector. It confirmed I am not alone in my belief that sentiment will eventually return to a positive stance even as the sector continues to locked in its deepest and longest bear market since the end of the financial crisis. I remain convinced the current entry points will look quite stellar one or two years out.</p><p>So why do I continued remain optimistic on the long term value of the sector?</p><p><strong>Growth:</strong></p><p>This was the fourth quarter in a row that profits within the S&amp;P 500 declined year-over-year, it was the fifth quarter in a row that revenues dropped from the same period a year ago. Seven of the 10 industry sectors within the S&amp;P showed profit and sales declines this quarter as domestic GDP growth clocked in with a .5% and global demand remains at depressed 2009 levels. In short, we are currently locked into a “profit recession” for the first time since the end of the financial crisis</p><p>In contrast, biotech companies within the S&amp;P 500 reported a 12% rise in revenues in the first quarter with commensurate gains in earnings. Despite all the political posturing on drug price “gouging” and the debacle of <strong>Valeant Pharmaceuticals (NYSE:</strong><a href="http://seekingalpha.com/symbol/VRX"><strong>VRX</strong></a><strong>),</strong> profit and sales growth remains strong within the sector. For all of 2015, spending on drugs domestically grew at a 12.2% clip to some $425 billion — an all-time record.</p><p><strong>Valuation:</strong></p><p>Despite being one of the few growth engines within the market, the collective valuation of the biotech companies within the S&amp;P 500 is at its lowest level in some five years around the time of the Greek Debt Crisis. Bargains abound among some of the large cap names in this sector. Take <strong>AbbVie (NYSE:</strong><a href="http://seekingalpha.com/symbol/ABBV"><strong>ABBV</strong></a><strong>),</strong> the drug maker primarily known for its blockbuster biologic Humira. Earnings should increase 15% to 20% both in FY2016 &amp; FY2017. The stock also pays a 3.6% dividend yield, twice that of a 10-year treasury right now. Despite this the stock goes for 13 times this year’s profits. <strong>Amgen (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/AMGN"><strong>AMGN</strong></a><strong>)</strong> is another large biotech concern that offers similar attributes.</p><p><strong>Innovation Continues:</strong></p><p>The bearish bent on biotech certainly not because innovation has dried up. New technologies that promise better and more effective treatments are increasing coming to the forefront. Immuno-therapy and Gene Editing are just two new focus areas that hold out great hope in discovering and developing treatments or cures to many dehabilitating diseases even potentially Alzheimer’s. Last year the FDA approved 56 New Drug Applications (NDAs), the second most on record.</p><p><strong>M&amp;A Should Pick Up:</strong></p><p>After a record year in 2014 and a very fast start through the first half of 2015, M&amp;A activity within the biotech and pharma sectors have gone dormant as these areas slid into bear market territory. In addition, the Treasury Dept. recently killed the $150 billion proposed tie up between <strong>Pfizer (NYSE:</strong><a href="http://seekingalpha.com/symbol/PFE"><strong>PFE</strong></a><strong>)</strong> and <strong>Allergan (NYSE:</strong><a href="http://seekingalpha.com/symbol/AGN"><strong>AGN</strong></a><strong>).</strong> However, now those two giants have to go “shopping” to continue to replenish their pipelines. Allergan has already made a number of smaller moves and has said it is mainly focused on “bolt on” acquisitions. This means a couple of small caps could receive some buyout attention from this Irish based giant. If it continues to build out its gastrointestinal product portfolio,<strong>Synergy Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/SGYP"><strong>SGYP</strong></a><strong>)</strong> has been a rumored target of Allergan. I think <strong>Progenics Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/PGNX"><strong>PGNX</strong></a><strong>)</strong> makes an ideal but complicated target. The oral version of Relistor should be approved in July, which will exponentially boost sales of this franchise. Distribution rights are owned by Valeant, but that company needs to sell assets to pay down its $30 billion in debt; so a two-part deal could be done.</p><p>Pfizer given its history is probably going to go after bigger fish and has been linked to the erstwhile bidding war for <strong>Medivation (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/MDVN"><strong>MDVN</strong></a><strong>).</strong> This is an oncology play that has doubled in the past month as it has already rejected a $9.3 billion offer from <strong>Sanofi (NYSE:</strong><a href="http://seekingalpha.com/symbol/SNY"><strong>SNY</strong></a><strong>).</strong> The concern looks destine to be bought out by one of the giants for north of $10 billion when all is said and done.</p><p>In addition, biotech juggernaut <strong>Gilead Sciences (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/GILD"><strong>GILD</strong></a><strong>)</strong> has a new leader who based on comments is more interested in pursuing M&amp;A especially now that blockbuster sales of its hepatitis C franchise are starting to decline. With some $15 billion in free cash flow and over $20 billion in cash on the balance sheet, Gilead could certainly make some significant purchases especially in focus areas of inflammatory diseases, oncology and liver diseases especially NASH where it has significant assets already. The company believes this could be the area that could provide its next blockbuster to go along with its market leading HIV and HCV franchises and is a ~$35 market five to six years out.</p><p><strong>Conclusion:</strong></p><p>While the current sentiment on biotech is indeed bearish, from a longer term perspective the bear market has created a very oversold sector within an overbought market. One, two or three years out, investors will probably look back on the entry points that are available now and wonder why they did not allocate more funds into the space.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/144/1*vzWwCo6zx6tj7psvMlSayg.png" /><figcaption>Bret Jensen</figcaption></figure><p>Thank You &amp; Happy Hunting</p><p>Bret Jensen<br>Founder, <a href="https://seekingalpha.com/account/research/subscribe?slug=bret-jensen&amp;source=bret_jensen_vurl">Biotech Forum</a></p><p><strong>Disclosure:</strong> I am/we are long ABBV, AGN, AMGN, GILD, PGNX, SGYP.</p><p>Stocks: <a href="http://seekingalpha.com/symbol/IBB">IBB</a></p><p><a href="https://seekingalpha.com/account/research/subscribe?slug=bret-jensen&amp;source=bret_jensen_vurl"><strong>For more information on Bret’s core investing strategy that is hugely successful in the lucrative biotech sector, consider Bret Jensen’s exclusive investment service, The Biotech Forum on Seeking Alpha.</strong></a></p><p><a href="http://eepurl.com/b2eq9v">FREE REPORTS SUBSCRIBE</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3dc16db194cb" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[4 Good Bets For Value & Yield In Biotech & Pharma — Bret Jensen]]></title>
            <link>https://medium.com/keeping-stock/4-good-bets-for-value-yield-in-biotech-pharma-bret-jensen-1b186f7eaa32?source=rss-38929c3b8ce2------2</link>
            <guid isPermaLink="false">https://medium.com/p/1b186f7eaa32</guid>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[The Biotech Forum]]></dc:creator>
            <pubDate>Fri, 20 May 2016 13:03:43 GMT</pubDate>
            <atom:updated>2016-05-20T13:03:43.755Z</atom:updated>
            <content:encoded><![CDATA[<p><strong>Note:</strong> A seven page investment report on a unique and attractively priced ~$6 biopharma stock will be sent free to my registered subscribers within the next 48 hours. Analysts believe these shares can double over the next 12–18 months and the company just signed a major collaboration deal with an industry heavyweight. These weekly reports on ‘bargains in biotech’ are yours free more than a week before data will be published on SA or Real Money Pro just by registering at <a href="http://www.bretjenseninvests.com/">bretjenseninvests.com</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/629/0*I0VBwdS4dhwZH9BG.jpg" /></figure><p>I just got back from the Money Show conference in Las Vegas where I delivered a couple of presentations. One on the state of the biotech sector and the other one where to find value in what I believe is at least a slightly overbought market with no earnings growth to speak of.</p><p>I found my audience a bit more somber than in years past although they seem to be maintaining their resiliency despite a very challenging market of the last year and a half. This contrasted to the mood at the nearby SALT conference in the Bellagio which is an annual hedge fund confab. After years of underperforming the market and seeing an increasing out migration of both governmental and corporate pension funds, this meeting of the financial “Masters of the Universe” was almost a wake. At least I hear it was, I think my invite might have got lost in the mail this year.</p><p>All kidding aside, it has been a rough go for both the retail and professional investor ever since the Federal Reserve drew down its last “quantitative easing” program in fall of 2014. Since then the market has gone basically sideways with more stocks down than up. The dollar has appreciated almost 20% since the summer of 2014, producing a major headwind for the earnings within the S&amp;P 500 which recently posted its fourth straight decline in earnings on a year-over-year basis.</p><p><em>(click to enlarge)</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*SqIXfqmLnVHU7452.jpg" /></figure><p>The energy sector has been tar pit that has left many investors with deep losses since oil began its descent from over $100 a barrel nearly two years ago. Even income investors have been brutalized as they leap into what they thought were “safe” yields provided via master limited partnerships (MLPs) within the energy sector.</p><p>Small caps have significantly underperformed the overall market over this time frame as well. This is despite little exposure to the strong dollar or tepid overseas demand. They have simply been hit as sentiment on the market has decidedly gone into a “risk off” mode and as volatility in the high yield credit markets spiked severely to start 2016. The latter has also caused most real estate investment trusts to substantially underperform the market since last summer as well, despite the yield on ten-year treasuries remaining below two percent.</p><p>Biotech has been taken out to the woodshed and treated like a rented mule since its last peak in July as that industry suffers it deepest and longest bear markets since the financial crisis. This has happened even as biotech was one of the few sub-sectors to produce over 10% growth in earnings and revenues this quarter in S&amp;P 500 this quarter.</p><p>In short, the current market is one that calls for continued caution and one that will likely to continue to punish investors looking for “home runs” and plays well for those happy with consistent “singles” at the moment. So where should investors channel their inner Wade Boggs or Rod Carew at the moment?</p><p>One has to love the large cap healthcare and biotech space despite both sectors recent travails. As noted above, this is one of the few areas of the market actually delivering both revenue and earnings growth right now despite a very challenging global backdrop. I have given enough “shout outs” to <strong>Amgen (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/AMGN"><strong>AMGN</strong></a><strong>)</strong> and <strong>AbbVie (NYSE:</strong><a href="http://seekingalpha.com/symbol/ABBV"><strong>ABBV</strong></a><strong>)</strong> in recent months on these pages so we will not cover them again but they should be on your buy on the dip “shopping lists”.</p><p><a href="http://eepurl.com/b2qF-T">PETXFreeReport</a></p><p><strong>Merck (NYSE:</strong><a href="http://seekingalpha.com/symbol/MRK"><strong>MRK</strong></a><strong>)</strong> also looks like a safe pick in current market environment. Its new hepatitis C products are gaining traction and should supplant the Viekera Pak as a solid #2 in this large, lucrative space behind market share leader <strong>Gilead Sciences (GILD</strong>). The shares pay almost three and a half percent dividend yield and go for slightly less than the overall market multiple based on earnings right now.</p><p><strong>Pfizer (NYSE:</strong><a href="http://seekingalpha.com/symbol/PFE"><strong>PFE</strong></a><strong>)</strong> looks like an even better bet as it is showing faster earnings growth than Merck and yields over 3.6%. The company is also going to use the huge declines among small and mid-cap concerns thanks to the “Yuge” bear market in the biotech space to do some bargain hunting. After its $150 billion merger to <strong>Allergan (NYSE:</strong><a href="http://seekingalpha.com/symbol/AGN"><strong>AGN</strong></a><strong>)</strong> was derailed on third try by the Treasury Dept., it certainly has the appetite to be a major player in the M&amp;A space.</p><p>The company had to rumored to be in the mix to purchase mid-cap oncology concern<strong>Medivation (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/MDVN"><strong>MDVN</strong></a><strong>)</strong>, but Monday morning announced the purchase for just over $5 billion of <strong>Anacor Pharmaceuticals (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/ANAC"><strong>ANAC</strong></a><strong>)</strong> which is a dermatology concern. Pfizer paid a 55% premium for Anacor but was able to pay in cash, a testament to the strength of its balance sheet and cash flow. I doubt Pfizer is done in replenishing its pipeline and is a solid bet at 14 times forward earnings given the stability of its cash flows and high dividend yield.</p><p>If Anacor is the first of several significant M&amp;A deals, this could be just the tonic for the biotech sector to finally rally out of this bear market; but that will be a topic for another column hopefully in the near future.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/144/1*vzWwCo6zx6tj7psvMlSayg.png" /><figcaption>Bret Jensen</figcaption></figure><p>Thank You &amp; Happy Hunting</p><p>Bret Jensen<br>Founder, <a href="http://biotechforumsa.com/">Biotech Forum</a></p><p><strong>Disclosure:</strong> I am/we are long ABBV, AMGN, MRK.</p><p>Stocks: <a href="http://seekingalpha.com/symbol/ABBV">ABBV</a>, <a href="http://seekingalpha.com/symbol/AMGN">AMGN</a>, <a href="http://seekingalpha.com/symbol/MRK">MRK</a>, <a href="http://seekingalpha.com/symbol/PFE">PFE</a></p><p><a href="http://bit.ly/biotechalpha"><strong>For more information on Bret’s core investing strategy that is hugely successful in the lucrative biotech sector, consider Bret Jensen’s exclusive investment service, The Biotech Forum on Seeking Alpha.</strong></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1b186f7eaa32" width="1" height="1" alt=""><hr><p><a href="https://medium.com/keeping-stock/4-good-bets-for-value-yield-in-biotech-pharma-bret-jensen-1b186f7eaa32">4 Good Bets For Value &amp; Yield In Biotech &amp; Pharma — Bret Jensen</a> was originally published in <a href="https://medium.com/keeping-stock">Keeping Stock</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Market Outlook: Landmines To Avoid — Bret Jensen]]></title>
            <link>https://medium.com/@biotech_forum/market-outlook-landmines-to-avoid-bret-jensen-b51105cac795?source=rss-38929c3b8ce2------2</link>
            <guid isPermaLink="false">https://medium.com/p/b51105cac795</guid>
            <category><![CDATA[donald-trump]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[finance]]></category>
            <dc:creator><![CDATA[The Biotech Forum]]></dc:creator>
            <pubDate>Wed, 27 Apr 2016 14:30:25 GMT</pubDate>
            <atom:updated>2016-04-27T14:30:25.439Z</atom:updated>
            <content:encoded><![CDATA[<blockquote><strong>Note:</strong> A 10 page report covering two small biotechs under $7.00 a share that are undervalued and could be possible takeout targets as well was just issued. Please click <a href="http://bit.ly/BiotechBuyout">here</a> for that free report. Our latest “The Trump Biotech Special: A $7 Development Concern With “Yuge” Potential” just was published on this morning and can be found <a href="http://bit.ly/TrumpSpecial">here</a>.</blockquote><p>To automatically get every free weekly report I put out on these type of biotech opportunities please just go to and register at <a href="http://www.bretjenseninvests.com/">bretjenseninvests.com</a>.</p><p>The S&amp;P 500 is approaching 52 week highs again and the deep losses to begin 2016 are starting to feel like a distant memory. However, with four straight quarters now of declining year-over-year earnings and a global economy that continues to be anemic; my view is there is not much upside in the overall market until we start to see some earnings growth. This will not happen until the second half of the year at the earliest.</p><p>That does not mean there are not still good places to invest, but as the cliché goes this is a true stock pickers market. I expect the overall market to be flat or slightly down when 2016 comes to a close. Where to invest and just as critically where not to put your funds will be critical to beating the market this year and producing a positive return within your portfolio in 2016. Let’s start with what sectors to avoid at the moment.</p><p>Technology is struggling at the moment thanks to a strong dollar and tepid overseas demand. Both <strong>Alphabet (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/GOOGL"><strong>GOOGL</strong></a><strong>)</strong> and <strong>Microsoft (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/MSFT"><strong>MSFT</strong></a><strong>)</strong> sold off last week after delivering their quarterly results and disappointing investors. In addition, demand for new issues has dried up completely pointing to the negative sentiment on the sector. There has only been one tech IPO so far in 2016. That was Dell cybersecurity unit <strong>SecureWorks (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/SCWX"><strong>SCWX</strong></a><strong>)</strong> which posted a flat debut even after downsizing its offering last week. I would underweight the sector at the moment.</p><p>Consumer Staples stocks have drawn a lot of money from the “safety” crowd in 2016 and have easily outperformed the market. However, with an average price earnings ratio north of 22, little in the way of growth and an average dividend yield a little above two percent right now; it is hard to see much in the way of value here at the moment. The same could be said of the Consumer Discretionary sector that has seen some of the same money flows and sports a slightly lower price earnings ratio but a much lower average dividend yield as well. I also have both of these sectors listed as an “Underweight”.</p><p>Banks and Insurers are having a tough time growing profits with the yield on the ten-year treasury stubbornly below two percent as central banks globally flood the market with liquidity. This is especially true as regulators and legislators continue to demand their pound of flesh this election year. I have the Financials as an “Underweight” for these reasons as well.</p><p>Finally, I would avoid any stocks that have sky-high multiples not supported by fundamentals such as cash flow growth. They are highly vulnerable to any disappointment. One only has to look at what happened to the shares of <strong>Netflix (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/NFLX"><strong>NFLX</strong></a><strong>)</strong> recently when it reported earnings that beat the consensus but did not delivered the robust guidance about international growth investors wanted to hear.</p><p><em>(click to enlarge)</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*qC5sBMZOQ65OY46a.jpg" /></figure><p>So what looks good in the current market? Well, the biotech sector has been surging recently and has been one of the strongest performing areas of the market so far in the second quarter of 2016. The sector is up some 20% now from its lows in February. I think we can finally safely say the longest and deepest bear market for the sector since the financial crisis is officially over.</p><p>Helping the sector is M&amp;A chatter is picking up again and the rally in crude oil has helped stabilized the high yield credit markets which is a tailwind to any small or mid-cap biotech concern that may need to access additional funding for developmental needs at some point in the foreseeable future. Large biotech stocks have benefited from investors coming to the realization this space is one of the few in the market that can deliver both earnings and revenue growth as the overall market is locked in a “profit recession”.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/1*xSS2NbdcAD8ww8sLoHH81A.jpeg" /><figcaption>www.bretjenseninvests.com</figcaption></figure><p>This week we get quarterly reports from industry stalwarts like <strong>AbbVie (NYSE:</strong><a href="http://seekingalpha.com/symbol/ABBV"><strong>ABBV</strong></a><strong>), Amgen (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/AMGN"><strong>AMGN</strong></a><strong>), Celgene (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/CELG"><strong>CELG</strong></a><strong>)</strong> and <strong>Gilead Sciences (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/GILD"><strong>GILD</strong></a><strong>).</strong> Both Amgen and Gilead have beaten the consensus for eight straight quarters. If results are strong once again, this may power the next leg of the recent rally as the sector is still more than 25% below its peak levels last July. I own all the names listed above and they are still good values in what feels like a slightly overbought market at the moment.</p><p>Although the housing market continues to recover in two step forward, one step back fashion; there is value in the home builders. Mortgage rates remains near historical lows, job creation continues to be solid but not spectacular and household formation is back above pre-recession levels. All this bodes well for a continued acceleration of housing activity. 2015 was the best year for housing starts since 2007 but even it was more than 20% below the 30-year average. In many markets the biggest obstacle for home sales in lack of inventory.</p><p>I continue to like all the homebuilders I have profiled in these pages this year including <strong>LGI Homes (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/LGIH"><strong>LGIH</strong></a><strong>), Taylor Morrison (NYSE:</strong><a href="http://seekingalpha.com/symbol/TMHC"><strong>TMHC</strong></a><strong>)</strong> and <strong>TRI Pointe Homes (NYSE:</strong><a href="http://seekingalpha.com/symbol/TPH"><strong>TPH</strong></a><strong>).</strong> For those wanting broader exposure to the sector, the <strong>SPDR Homebuilders ETF (NYSEARCA:</strong><a href="http://seekingalpha.com/symbol/XHB"><strong>XHB</strong></a><strong>)</strong> can easily be tucked into one’s portfolio.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/320/0*KeVWo2mQ6vqg7t74.jpg" /></figure><p>That is my take on the current market.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/131/1*unbu4U97fnwU1HFN6zziIQ.png" /><figcaption>Bret Jensen</figcaption></figure><p>Thank You &amp; Happy Hunting!<br>Bret Jensen<br>Founder, <a href="https://seekingalpha.com/account/research/subscribe?slug=bret-jensen&amp;source=bret_jensen_vurl">Biotech Forum</a></p><p><strong>Disclosure:</strong> I am/we are long ABBV, AMGN, CELG, GILD, LGIH, TMHC.</p><p><em>Originally published at </em><a href="http://seekingalpha.com/instablog/498952-bret-jensen/4876869-market-outlook-landmines-avoid"><em>seekingalpha.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b51105cac795" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[3 Attractive Biotech Stocks Insiders Are Buying — Bret Jensen]]></title>
            <link>https://medium.com/keeping-stock/3-attractive-biotech-stocks-insiders-are-buying-bret-jensen-cd13c707279a?source=rss-38929c3b8ce2------2</link>
            <guid isPermaLink="false">https://medium.com/p/cd13c707279a</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[stock-market]]></category>
            <category><![CDATA[investing]]></category>
            <dc:creator><![CDATA[The Biotech Forum]]></dc:creator>
            <pubDate>Tue, 26 Apr 2016 15:24:25 GMT</pubDate>
            <atom:updated>2016-04-26T15:24:25.165Z</atom:updated>
            <content:encoded><![CDATA[<blockquote><strong>Mark Your Calendars:</strong> Our recent Tax Day free two week trial offer expanded our <a href="http://seekingalpha.com/author/bret-jensen/research">Biotech Forum</a> Community by 30%. Several followers have stated they missed this opportunity. As such we are bringing it back for a limited time this coming May Day weekend. From 6am EST Friday to midnight on Monday, May 1st our free two week trial period will be enabled. I hope all interested biotech investors take advantage of this offer and give the Biotech Forum a whirl. Not only has the Biotech Forum portfolio easily outperformed its benchmark since launch but the Live Chat feature has grown expontentially. It is quite the lively and knowledgeable group during the trading day. It is a great place to get new ideas or offer them.</blockquote><p>Now back to our regularly scheduled program!</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/574/0*akv805fYP6ap-noY.jpg" /></figure><p>The market has staged an impressive rally over the past few months after deep early losses that were incurred in the beginning weeks of 2016. The fears around high yield credit and other myriad “worst case” concerns about a hard landing in China or even a global recession have not materialized. Oil that was nearing $25 a barrel near the nadir of the descent in the market has rebounded back into the mid-$40s. While not even near the over $100 a barrel that existed for years before the big decline in crude began the summer of 2014, this rise has improved sentiment and stock prices in the energy sector as well as many emerging markets. It has also lower the volatility in our markets as well.</p><p><em>(click to enlarge)</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*wo1FKTuj-coyVkAI.jpg" /></figure><p>One big tell that the market was overcorrecting early in the year was insider buying activity; which hit a multi-year high a few months ago when stocks were selling off. The fact that so many corporate directors and high level management thought their equities were undervalued was a tip-off that things were not as bad as the market was portraying. It also looks like the correct view given the recent broad based rally in the stock market.</p><p>However, after this big rise the market does feel more than fairly valued given we are in the fourth quarter in a row where profits within the S&amp;P 500 have declined year-over-year and the second quarter looks poised to run that streak to five. So which stocks still look good to insiders despite the recent rally in the market? Well, after the deep bear market in biotech which looks like it has recently ended; there is some significant insider buying still going on in the small and mid-cap names in that sector. Here are a few that look attractive to me at current levels.</p><p>Let’s start with <strong>Opko Health (NYSE:</strong><a href="http://seekingalpha.com/symbol/OPK"><strong>OPK</strong></a><strong>),</strong> a biopharmaceutical and diagnostic concern down here in Miami, which I have mentioned before and that continues to show strength after a recent and temporary setback. Insiders have bought over two million shares of this stock over the past six months in over five dozen different transactions. That buying continues and is mainly led by noted biotech billionaire and entrepreneur Dr. Phillip Frost.</p><p>The stock is back above $11.00 a share after getting below $8.00 a share in February. Revenues should more than double this year to over $1 billion and the company should move from small losses to a solid profit in FY2017. If and when its compound Rayaldee is approved for one aspect of chronic kidney disease, which looks likely; expect the shares to move up further. The company’s business consists of the nation’s third-largest clinical laboratory with a core genetic testing business as well as an expanding biologic product portfolio and solid late stage pipeline.</p><p><strong>Ardelyx (NASDAQ:</strong><a href="http://seekingalpha.com/symbol/ARDX"><strong>ARDX</strong></a><strong>)</strong> is another biopharma concern I recently came across that has an attractive <a href="http://www.ardelyx.com/products/">pipeline</a> and significant insider buying. This company has a $300 million market capitalization and focuses on developing and commercializes minimally-systemic therapeutics for the gastrointestinal (NYSE:<a href="http://seekingalpha.com/symbol/GI">GI</a>) tract to treat GI and cardio-renal diseases.</p><p>Its primary compound being developed as a possible treatment against constipation-predominant irritable bowel syndrome (IBS-C) and for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Two Phase III trials were initiated for the treatment of IBS-C in the fourth quarter of 2015. A second Phase 2b study for hyperphosphatemia, which is an elevated level of phosphate in the blood, was initiated around the same time.</p><p>It second lead compound is in Phase II trials as a possible treatment against hyperkalemia and looks promising. Earlier this year the compound the company did a $75 million secondary offering early this year to raise the necessary funding for development. Insiders bought most of the secondary offering, which is rare and have made some small purchases on the open market since. Given the company could have as many as three New Drug Applications (NDA) by the end of 2017 for addressable markets, I can see the logic behind such enthusiasm especially with the stock at a little less than $9.00 a share.</p><p>Moving way out on the risk scale we end with a small San Diego based biotech concern named aTyr Pharma which the memorable ticker symbol of LIFE. Two things intrigued me around this small cap when it popped up on my radar screen over the past few days. First, several insiders have bought almost 400,000 shares recently. Second, the cash on its balance sheet is roughly equal to the market capitalization of the company, a rare quiniela for track racing fans.</p><p>LIFE is what I call a “busted IPO”. The company came public in May of last year and soon was above $25.00 a share. After the hyperbole of its IPO wore off and investors moved on to the next hot thing, the shares declined and now sell at just $4.00 a share. LIFE engages in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators.</p><p>The company has a very early stage pipeline and the firm did have some turnover in the executive suite earlier this year. However, given the insider buying, cash on the balance sheet and at one-time price targets as high as $42.00 a share from analysts; I picked up a few shares last week and now have the company on my “watch list”. Insiders seem to be signaling the company might someday live up to the initial expectations of the market when it came public.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/131/1*unbu4U97fnwU1HFN6zziIQ.png" /><figcaption>Bret Jensen</figcaption></figure><p>Thank You &amp; Happy Hunting</p><p>Bret Jensen</p><p>Founder, <a href="https://seekingalpha.com/account/research/subscribe?slug=bret-jensen&amp;source=bret_jensen_vurl">Biotech Forum</a></p><p><strong>Disclosure:</strong> I am/we are long ARDX, OPK.</p><p><em>Originally published at </em><a href="http://seekingalpha.com/instablog/498952-bret-jensen/4876055-3-attractive-biotech-stocks-insiders-buying"><em>seekingalpha.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=cd13c707279a" width="1" height="1" alt=""><hr><p><a href="https://medium.com/keeping-stock/3-attractive-biotech-stocks-insiders-are-buying-bret-jensen-cd13c707279a">3 Attractive Biotech Stocks Insiders Are Buying — Bret Jensen</a> was originally published in <a href="https://medium.com/keeping-stock">Keeping Stock</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>